Kosuke Ichikawa

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Satoshi Watanabe, Junta Tanaka, Takeshi Ota et al. · BMC Cancer · 2011 · 394 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia

Junko Baba, Satoshi Watanabe, Yu Saida et al. · Blood · 2012 · 74 citations · Full text

Life Sciences, Immunology, Oncology +14

A Phase II Study of Irinotecan for Patients with Previously Treated Small-Cell Lung Cancer

Rie Kondo, Satoshi Watanabe, Satoshi Shoji et al. · Oncology · 2018 · 45 citations

Medicine, Oncology, Pharmacology +17

Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy

Yu Saida, Satoshi Watanabe, Tomohiro Tanaka et al. · The Journal of Immunology · 2015 · 29 citations · Full text

Life Sciences, Immunology, Oncology +17

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity

Masashi Arita, Satoshi Watanabe, Nobumasa Aoki et al. · Scientific Reports · 2021 · 27 citations · Full text

Medicine, Oncology, Pharmacology +13